On June 5–6, the Global Think-tank on Steatotic Liver Disease convened a multidisciplinary group of 125 participants in Barcelona, including clinicians, patient advocates, public health experts, and…
It's okay for your liver to have a little fat. But if more than 5% of your liver's weight is fat, you have MASLD, which stands for metabolic dysfunction–associated steatotic liver…
Emerging screening methods may support earlier diagnosis and intervention in thyroid eye disease (TED) care. In a recent MedCentral article, AACE President Scott D. Isaacs, MD, FACP, FACE, explains…
In this Wall Street Journal feature, AACE President Scott D. Isaacs, MD, FACP, FACE, offers expert insight into the growing use of personalized nutrition tools like microbiome tests and continuous…
Tirzepatide (TZP) was associated with improved metabolic parameters and gonadal hormone levels in male patients with obesity and metabolic hypogonadism, according to findings of an Italian pilot…
Thyroid disorders and menopause can share many overlapping midlife symptoms, often described as “nonspecific,” making it difficult to determine the underlying cause. AACE President Scott D. Isaacs,…
The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. AACE President Scott D.…
The FDA has expanded Wegovy use to include adults with metabolic-associated steatohepatitis (MASH) and moderate to severe fibrosis, or scarring in the liver. AACE President Scott D. Isaacs, MD, FACP…
Serena Williams is opening up about her weight loss journey with GLP-1 medication Zepbound, helping to change the conversation around obesity care. AACE President Scott D. Isaacs, MD, FACP, FACE,…